ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their price targets and ratings for several US-listed companies, including monday.com, G1 Therapeutics, Cadence Design Systems, The Children's Place, AN2 Therapeutics, Lattice Semiconductor, Trimble, ZoomInfo Technologies, PayPal Holdings, and The Duckhorn Portfolio. These changes reflect analysts' latest views on these stocks, with some experiencing upgrades and others downgrades.
February 13, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham increased Cadence Design Systems' price target from $315 to $320, maintaining a Buy rating.
The raised price target by Needham suggests a bullish outlook on Cadence Design Systems, indicating a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised Lattice Semiconductor's price target from $80 to $85, maintaining an Overweight rating.
The increase in price target by Keybanc suggests a positive outlook on Lattice Semiconductor, potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised the price target for monday.com from $238 to $242, maintaining an Overweight rating.
The increase in price target by Keybanc suggests a positive outlook on monday.com, potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler upgraded Trimble from Neutral to Overweight, raising the price target from $51 to $68.
The upgrade to Overweight and price target increase by Piper Sandler indicate a bullish outlook on Trimble, suggesting a potential short-term price rise.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler increased ZoomInfo Technologies' price target from $23 to $24, maintaining an Overweight rating.
The slight increase in price target by Piper Sandler suggests a continued positive outlook on ZoomInfo Technologies, potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Needham cut G1 Therapeutics' price target from $14 to $12 but maintained a Buy rating.
Despite the price target cut, the maintenance of a Buy rating indicates a continued positive outlook, likely neutralizing short-term impact.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Daiwa Capital downgraded PayPal Holdings from Outperform to Neutral, cutting the price target from $64 to $62.
The downgrade to Neutral and minor price target cut by Daiwa Capital suggest a cautious outlook on PayPal Holdings, likely leading to a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform, reducing the price target from $23 to $7.
The downgrade and significant price target reduction by Leerink Partners suggest a bearish view on AN2 Therapeutics, indicating a potential short-term price drop.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 95
NEGATIVE IMPACT
B of A Securities downgraded The Duckhorn Portfolio from Neutral to Underperform, lowering the price target from $11 to $8.
The downgrade to Underperform and price target reduction by B of A Securities indicate a negative outlook on The Duckhorn Portfolio, suggesting a potential short-term price decline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
B. Riley Securities downgraded The Children's Place from Neutral to Sell, cutting the price target from $19 to $4.
The downgrade to Sell and significant price target cut by B. Riley Securities indicate a strong negative outlook, likely leading to a short-term price decline.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 95